Health Care · Medicinal Chemicals & Botanical Products

NAGE Niagen Bioscience, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1386570109 filings
Russell 2000

NAGE at a glance

Niagen Bioscience, Inc. (NAGE, SEC CIK 1386570) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as July 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Niagen Bioscience, Inc. (NAGE) reported revenue of $129.4 million (up 29.9% from FY2024) and net income of $17.4 million. Diluted EPS was $0.20.
  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Niagen Bioscience, Inc. (NAGE) shares worth $39.6 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$129.4M
+29.9% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
22 funds
$39.6M · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02 · Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Competitive risk: FDA’s September 2025 NMN decision increased lower-priced competition, with ingredient-business financial impacts already experienced
  • Legal risk: Elysium fee award of approximately $9.2 million reversed October 30, 2026, but further review remains possible
  • Regulatory risk: Putative consumer class actions challenge Tru Niagen® advertising and marketing claims
  • Operational risk: Marketplace suspension of a Tru Niagen® listing during Q2 2026 caused lost revenue
  • Liquidity risk: $69.5 million cash and no line-of-credit borrowings outstanding, with additional financing potentially required beyond twelve months

Management Discussion & Analysis

  • Q3 revenue $27.2M, down 20% YoY from $34.0M, driven by Consumer Products and Ingredients declines
  • Ingredients worst segment: sales $3.8M, down 47%; Consumer Products best: sales $23.3M, down 10%
  • Gross margin 62.9% vs 64.5% YoY, with Ingredients margin 51.3% vs 59.1%
  • Cash $69.5M at September 30; operating cash flow $4.2M vs $12.8M YoY
  • $5.1M investing inflow from divestiture; $4.6M financing outflow including $5.1M share repurchases
  • Near-term headwinds: softer downstream demand, variable partner orders, competitive pricing, and elevated marketing investment

AI summary of the NAGE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 earnings announcement for quarter ended September 30, 2026
  • Exhibit 99.1 contains Niagen Bioscience’s detailed financial results and management commentary

Item 7.01: Regulation FD Disclosure

  • Corporate presentation released November 4, 2026, providing updated company information to investors
  • Exhibit 99.2 contains the presentation, including potentially material business and strategic updates

Item EX-99.1: Item EX-99.1

  • Q3 net sales $27.2M, down from $34.0M; Tru Niagen contributed $23.3M
  • Gross margin 62.9%, while net loss reached $1.2M versus $4.6M net income last year

Item EX-99.2: Item EX-99.2

  • Q3 2026 earnings presentation: net sales $27.2M, down 20% year over year, with Tru Niagen sales $23.3M
  • Profitability weakened: gross margin 62.9% versus 64.5%, net loss $(1.2)M, and Adjusted EBITDA $0.5M versus $6.4M
Filed Aug 4, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 sales $29.8M, down from $31.1M; Tru Niagen contributed $24.2M while direct-to-consumer sales grew 23% year-over-year
  • Gross margin 64.8%; operating income fell to $0.7M from $3.2M as operating expenses increased to $18.6M

Item 2.02: Results of Operations and Financial Condition

  • Earnings release covers quarter ended June 30, 2026
  • Exhibit 99.1 contains Niagen Bioscience’s reported quarterly financial results

Item 7.01: Regulation FD Disclosure

  • Corporate presentation released August 4, 2026, providing updated company information to investors
  • Exhibit 99.2 contains the presentation, including any strategic, operational, or financial updates disclosed by Niagen Bioscience

Item EX-99.2: Item EX-99.2

  • Q2 net sales $29.8M, down from $31.1M, while Tru Niagen sales rose to $24.2M from $22.7M
  • Gross margin 64.8%, net income $1.0M, diluted EPS $0.01, and Adjusted EBITDA $3.0M
Filed Jun 29, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All eight director nominees elected for terms through the 2027 annual meeting
  • Steven Rubin and Hamed Shahbazi received notably higher withheld votes, signaling greater shareholder dissent

AI summaries of NAGE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NAGE

Don't miss the next NAGE filing

  • Alerts as it files. A push when NAGE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NAGE, by share count.
  • Ask anything. An AI agent that reads every NAGE filing and answers with sources.

NAGE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Fried Robert NAJun 30, 2026$2.71
Lopez Carlos LuisAJun 30, 2026$2.71
Pamir OzanAJun 30, 2026$2.71
YU Wing Tak WendyAJun 24, 2026-
Patrick KristinAJun 24, 2026-
Shahbazi HamedAJun 24, 2026-
Rubin Steven DAJun 24, 2026-
Ng Wang Yu GaryAJun 24, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$99.6M$129.4M
Gross Profit$50.8M$61.6M$83.2M
Operating Income-$7.7M$16.3M
Net Income-$4.9M$8.6M$17.4M
Gross Margin-61.8%64.3%
Op. Margin-7.8%12.6%
Net Margin-8.6%13.4%
Balance Sheet
Total Assets-$68.3M$106.4M
Equity$28.5M$46.1M$76.5M
ROE-17.4%18.5%22.7%
Per Share
EPS$-0.07$0.11$0.20
Cash Flow
Operating CF-$12.1M$13.5M

Source: XBRL data in Niagen Bioscience, Inc. (NAGE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NAGE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NAGE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$39.6M
Q2 202624$47.4M
Q1 202627$73.0M
Q4 202527$106.2M
Q3 202527$152.4M
Q2 202527$218.5M
Q1 202524$69.3M
Q4 202420$41.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 198 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NAGE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
8-KAug 4, 2026Analysis-
10-QAug 4, 2026Analysis
SC 13GJul 29, 2026-
4Jul 8, 2026--
4Jul 8, 2026--
4Jul 8, 2026--
8-KJun 29, 2026Analysis-
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
8-KMay 6, 2026Analysis
10-QMay 6, 2026Analysis
4Apr 27, 2026--
8-KMar 19, 2026Analysis-
8-KMar 4, 2026Analysis-
10-KMar 4, 2026-
8-KFeb 26, 2026Analysis-
4Feb 24, 2026--
8-KDec 22, 2025-

Related Health Care companies

All Health Care →

NAGE SEC filings: frequently asked questions

Which institutions hold NAGE stock?

As of September 30, 2026, the largest Niagen Bioscience, Inc. (NAGE) holders among the 13F filers tracked by SignalX were BlackRock ($11.9 million), Vanguard Capital Management LLC ($6.4 million), Goldman Sachs Group ($4.3 million), Vanguard Portfolio Management LLC ($3.4 million), State Street Corp ($3.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NAGE's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Niagen Bioscience, Inc. (NAGE) reported revenue of $129.4 million (up 29.9% from FY2024) and net income of $17.4 million. Diluted EPS was $0.20. The figures come from the XBRL data in the 10-K.

What did NAGE report in its latest 8-K?

Niagen Bioscience, Inc. (NAGE) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 fiscal 2026 earnings announcement for quarter ended September 30, 2026.

What are the latest NAGE SEC filings?

Niagen Bioscience, Inc. (NAGE) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on July 8, 2026.

What is NAGE's SEC CIK number?

Niagen Bioscience, Inc. (NAGE)'s SEC Central Index Key (CIK) is 1386570. EDGAR lists every NAGE filing under that number.

Ask anything about NAGE

The research agent reads NAGE's filings, financials, insider trades and 13F holders, then answers with sources.